

Anti-TMPRSS2

Catalog No.	Description		
AMD12-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
AMD12-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive TM Detection Systems and i6000 TM Automated Staining Systems		
MUD12-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
MUD12-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
AXD12-YCD	Ready-to-Use Antibody in Barcode labelled vial for use on the Xmatrx [®] Elite Staining System, 160 tests		
AXD12-50D	Ready-to-Use Antibody in Barcode labelled vial for use on the Xmatrx [®] Elite Staining System, 50 tests		
AXD12-4M	Ready-to-Use Antibody in Barcode labelled vial for use on the NanoVIP® Staining System, 50 tests		

Clone	Species	Ig Class
H-4	Mouse	IgG1, kappa

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of human TMPRSS2 in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

TMPRSS2 also designated PRSS10 or Transmembrane protease serine 2 or Serine protease 10, is a 492 amino acid type II transmembrane multimeric serine protease that belongs to the serine protease family. It contains type II transmembrane domain, a scavenger receptor cysteine-rich domain of group A, a LDL receptor class A domain and a serine protease domain. Serine proteases are involved in many physiological and pathological processes and this glycosylated serine protease is regulated by androgens. TMPRSS2 is expressed as a full length form and a cleaved protease domain on the plasma membrane of human bronchial epithelial cells, nasal goblet cells, small intestine epithelia, gastrointestinal tract, salivary gland, kidneys and pancreas. High expression of TMPRSS2 is seen in prostate tissue, prostate cancer cells and lower expression levels are observed in the androgen-independent prostate cancer tissue, epithelia of the colon, stomach, epididymis and breast tissue.

Emergo Europe, Westervoortsedijk 60, 6827 AT Arnhem, The Netherlands

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The primary antibody may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody human TMPRSS2 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations	
Control Tissue	Prostate carcinoma, prostate, Kidney tissue as available with Biogenex FB-D12M* & FG-D12M*	
Recommended Dilution for Concentrated Antibody	1:20-50 in HK941	
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)	
Recommended Pretreatment (Xmatrx & NanoVIP)	EZ-AR2 Elegance (HX032-YCD & HX046- 08XN)	
Antibody Incubation (Manual/i6000)	30-60 Min at RT	
Antibody Incubation (Xmatrx & NanoVIP)	30-60 Min at 25°C	
Detection System for Manual, Xmatrx, NanoVIP & i6000 systems***	Use BioGenex Two-Step OR One-Step Super Sensitive [™] Polymer-HRP IHC Detection System/DAB; see p. 2 for more information	

Category	Antibodies	Revision No.	В
Document No.	932-D12M-EN	Release Date	19-Jan-2024



*FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx & NanoVIP requires micro chamber

Pretreatment times will vary based on individual microwave power. *For automation systems (Xmatrx-Elite, NanoVIP & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection	Two-Step	One-Step	Link and
System	HRP Kit	HRP Kit	Label Kit
Manual	QD440-XAKEN (1000 Test) QD430-XAKEN (1000 Test)	QD630-XAKEN (1000 Test)	QP300- XAKE (1000 Test)
Manual	QD420-YIKEN (500 Test) QD400-60KEN (60 Test)	QD620-XAKEN (500 Test)	QP900- 9LE (500 Test)
Xmatrx - Automation	QD550-YCDEN (200 Test)	QD610-YADEN (200 Test)	N/A
NanoVIP- Automation	QD551-YCDEN (100 Test)	QD611-YADEN (100 Test)	N/A
i6000 - Automation	QD410-YAXEN (200 Test)	QD610-YAXEN (200 Test)	N/A

For more information, visit www.biogenex.com.

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

Expected Results

This antibody stains membrane in positive cells in formalinfixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the Emergo Europe, Westervoortsedijk 60, 6827 AT Arnhem, The Netherlands

product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- Clark, J., Cooper, C. (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6, 429-439. PMID: 19657377.
- 2. Duffy, MJ. (2014) Chapter One PSA in Screening for Prostate Cancer: More Good than Harm or More Harm than Good? Adv Clin Chem. 66:1-23.
- Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W. (2017) TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie. 142:1-10.

2°C 8°C	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
\boxtimes	Use By Date	LOT	Batch Code
NON STERILE	Non-Sterile	[]i	Consult Instructions for Use
EC REP	Representative in the European Community	***	Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	В
Document No.	932-D12M-EN	Release Date	19-Jan-2024